Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Clinical Guideline From the American College of Physicians
Methodological detailsbased on systematic review and network meta-analysis, GRADE approach
- Based on systematic review and network meta-analysis
- GRADE approach
Recommendations
As issued by the authors
- strong recommendation; high-certainty evidence
Add an SGLT-2 inhibitor or GLP-1 agonist to metformin and lifestyle modifications in adults with T2D and inadequate glycemic control. Use an SGLT-2 inhibitor to reduce risk of all-cause mortality, MACE, CKD progression and hospitalization for congestive HF; use a GLP-1 agonist to reduce risk of all-cause mortality, MACE and stroke.
- strong recommendation; high-certainty evidence
Recommends against adding a DPP-4 inhibitor to metformin and lifestyle modifications in adults with T2D and inadequate glycemic control to reduce morbidity and all-cause mortality.
Original publication
Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Clinical Guideline From the American College of Physicians. Ann Intern Med. Published 19 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →